As the Democratic Republic of the Congo and neighboring regions confront the fastest-growing Ebola outbreak ever recorded, GeoVax Labs, Inc. (Nasdaq: GOVX) is drawing attention to its MVA-based vaccine platform and hemorrhagic fever vaccine candidates that could potentially aid in the crisis. The outbreak, caused by the Bundibugyo virus (BDBV), has already resulted in more than 4,300 cases and 2,000 deaths, according to the World Health Organization (WHO), and is on a trajectory that could surpass the death toll of the 2014-2016 West Africa Ebola epidemic. Notably, there is currently no approved vaccine specifically targeting Bundibugyo virus.
GeoVax, a biotechnology company focused on infectious diseases and cancers, has conducted extensive preclinical development on vaccine candidates against Zaire ebolavirus, Sudan ebolavirus, and Marburg virus, all built on its Modified Vaccinia Ankara (MVA) platform. These candidates have demonstrated encouraging protective efficacy in non-human primate lethal-challenge studies. The company is now signaling its readiness to engage with global health authorities, including the WHO and Africa CDC, to explore how its technology and expertise might contribute to the response.
"The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs," said David Dodd, Chairman and CEO of GeoVax. "We are prepared to engage with WHO, Africa CDC, national public health authorities, and other appropriate organizations to determine whether our vaccine candidates, technology, or scientific expertise could contribute to the response. Where appropriate, we are also willing to make relevant vaccine materials available for evaluation against Bundibugyo virus."
GeoVax's lead infectious disease priority remains GEO-MVA, its MVA-based vaccine for mpox and smallpox, which is advancing toward a pivotal clinical program. The company is already building relationships with healthcare and research organizations in Africa, partly for the GEO-MVA trials, but these connections also provide a channel to explore collaborative efforts against Ebola. "Our relationships in the region are being developed first and foremost to advance GEO-MVA, but many of the organizations with whom we are engaging are simultaneously confronting this Ebola outbreak," Dodd commented. "Given our experience, we believe it is appropriate to ask how we might help."
The broader MVA portfolio offers strategic optionality beyond GEO-MVA. GeoVax is open to discussing collaborations, licensing arrangements, and public-private partnerships that could bring external resources to further evaluate and develop these candidates without diverting primary resources from its lead program. The company's combination of MVA platform expertise, hemorrhagic fever vaccine candidates, and efforts to advance scalable MVA manufacturing positions it as a potential partner in addressing emerging infectious disease threats.
GeoVax's GEO-MVA program is designed to provide an independent and scalable source of MVA vaccine supply, addressing historical limitations such as manufacturing scalability and the need for multiple doses. The company is exploring innovations like continuous cell-line manufacturing and single-dose regimens. As the Ebola outbreak continues to expand, GeoVax's willingness to contribute its expertise and assets could play a role in bolstering global preparedness and response capabilities.
